Performance of the Alere i RSV assay for point-of-care detection of respiratory syncytial virus in children by Schnee, Sarah V. et al.
RESEARCH ARTICLE Open Access
Performance of the Alere i RSV assay for
point-of-care detection of respiratory
syncytial virus in children
Sarah Valerie Schnee1,2,3†, Johannes Pfeil1*† , Clara Marlene Ihling2,3, Julia Tabatabai1,2,3 and Paul Schnitzler3
Abstract
Background: Respiratory syncytial virus (RSV) is the most important cause of severe acute respiratory tract infection
in young children. Alere i RSV is a novel molecular rapid test which identifies respiratory syncytial virus in less than
13 min.
Methods: We evaluated the clinical performance of the Alere i RSV assay in a pediatric point-of-care setting during
winter season 2016 / 2017. Test results from 518 nasopharyngeal swab samples were compared to a real-time
reverse transcription PCR reference standard.
Results: The overall sensitivity and specificity of the Alere i RSV test assay was 93% (CI95 89% – 96%) and 96% (CI95
93% – 98%), respectively. Alere i RSV performed well in children of all age groups. An optimal sensitivity of 98%
(CI95 94% - 100%) and specificity of 96% (CI95 90% - 99%) was obtained in children < 6 months. In children ≥ 2
years, sensitivity and specificity remained at 87% (CI95 73% – 96%) and 98% (CI95 92% – 100%), respectively. False
negative Alere i RSV test results mostly occurred in samples with low viral load (mean CT value 31.1; CI95 29.6 – 32.
6). The Alere i RSV assay is easy to use and can be operated after minimal initial training. Test results are available
within 13 min, with most RSV positive samples being identified after approximately 5 min.
Conclusion: The Alere i RSV assay has the potential to facilitate the detection of RSV in pediatric point-of-care
settings.
Background
Respiratory Syncytial Virus (RSV) is the most important
cause of acute respiratory tract infection (aRTI) in
neonates and young children worldwide [1]. RSV is a fre-
quent cause of hospitalization in young children and leads
to significant morbidity in premature neonates and chil-
dren with chronic lung or congenital heart disease [2–4].
The clinical diagnosis of RSV is hampered by the
mostly unspecific symptoms of RSV infection. Early
recognition of RSV infection is useful to optimize care
management, minimize unnecessary antibiotic use [5]
and provide targeted infection control for children hos-
pitalized with RSV infection [6]. In addition, specific
antiviral therapy for RSV infection is currently under
early clinical evaluation [7], and early detection of RSV
infection may become important for timely antiviral
treatment in severely sick children.
Pediatricians therefore often apply rapid point-of-care
RSV test assays. The major limitation of point-of-care
RSV testing is the low sensitivity of commercially avail-
able rapid antigen detection tests (RADT). RADT sensi-
tivity is strongly dependent on viral load, and therefore
performs best in young infants with classical symptoms
of RSV bronchiolitis. In older children and adults with
low viral load, the sensitivity is poor and RADT are not
recommended in these age groups [8, 9].
Alere i RSV is a novel rapid molecular test assay which
can identify RSV in less than 13 min. In a previous ana-
lysis, we reported an Alere i RSV sensitivity and specifi-
city of 100% (CI95 89–100%) and 97% (CI95 89% –
100%), respectively [10]. This first analysis focused on
young infants, and testing was done under laboratory
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conditions which may not reflect the performance in
point-of-care settings.
In the current study, we addressed these limitations
and applied the Alere i RSV test assay in a pediatric
point-of-care setting on a larger study population across
different pediatric age groups. The objective of this
analysis was to report an estimate of the Alere i RSV test
performance in a pediatric point-of-care setting.
Methods
Study cohort and sampling procedure
Between November 2016 and March 2017, we prospect-
ively collected 533 nasopharyngeal swabs (NPS) in the
outpatient department of the Center of Childhood and
Adolescent Medicine Heidelberg, Germany. Study inclu-
sion criteria were I) age < 18 years, II) clinical symptoms
of an acute respiratory infection, and III) indication for
hospitalization according to the clinical judgment of the
attending physician. Patients with clinical symptoms of
an acute respiratory infection included cases of upper
respiratory tract infection (URTI), otitis media, croup,
bronchiolitis, bronchitis and pneumonia.
Nasopharyngeal swabs were collected by local staff in
1 ml viral transport media (VTM; MSwab; Copan,
Brescia, Italy). 200 μl of the VTM were directly used for
point-of-care testing with the Alere i RSV assay. The
remaining sample was transferred to the virology diag-
nostic laboratory, and stored in 200 μl aliquots at −80 °C
until further analysis.
Attending pediatricians prospectively reported med-
ical information on a standardized data sheet, includ-
ing the duration of clinical symptoms, demographic
and clinical data.
Alere i RSV assay
Alere i RSV test assays were applied in the pediatric out-
patient department. The test procedure followed the
Alere i RSV package insert [11]. In brief, 200 μl of the
respiratory sample was added to the sample receiver
containing 2.5 ml elution buffer. Two 100 μl volumes
were added to the test base with the provided transfer
cartridge for isothermal amplification.
Alere i RSV assays were conducted by attending physi-
cians or nurses working in the pediatric outpatient
department. All operators were allowed to carry out the
test assay only after an initial hands-on-training. Test
results were printed and reported on the medical data-
sheet. Invalid test results were re-tested immediately.
Reference standard (RT-PCR test procedures)
The Alere i RSV assay was evaluated against a CE-
marked real-time reverse transcriptase polymerase chain
reaction assay (RT-PCR).
For RT-PCR analysis, RNA was extracted from 140 μl
respiratory specimen using the QIAamp® viral RNA mini
kit (Qiagen, Hilden, Germany) according to the manu-
facturer’s protocol. Amplification and detection of viral
RNA was performed by FTD respiratory pathogens 21
multiplex PCR (FTD 21, Fast-track diagnostics Ltd.,
Sliema, Malta) on a LightCycler® 480 instrument II
(Roche, Mannheim, Germany). The FTD 21 assay can
detect the following pathogens: influenza A, H1N1 or B,
rhinovirus, respiratory syncytial virus, bocavirus, adeno-
virus, parainfluenza 1, 2, 3 or 4, coronavirus NL63,
229E, OC43 or HKU1, parechovirus, enterovirus, human
metapneumovirus A/B and Mycoplasma pneumoniae.
FTD 21 results that did not correspond to the Alere i
test assay were verified by a second RT-PCR assay. For
this purpose, RNA was extracted from an independent
sample aliquot and analyzed by altona RealStar PCR
(altona RealStar RSV RT-PCR, altona Diagnostics,
Hamburg, Germany). To preclude possible discrepancies
between the two RT-PCR methods, samples with differ-
ent results in monoplex and multiplex PCR were again
tested by the FTD 21 assay (Additional file 1: Figure S3).
Both the FTD 21 and the altona RealStar assay were
initially evaluated using defined RSV A and RSV B posi-
tive and negative samples from patients, from the
German RSV reference laboratory and from the official
German proficiency testing panel. Results with a cycle
threshold (CT) value of <35 were considered positive.
For sub-typing of RSV positive samples, Sanger sequen-
cing targeting the second hyper-variable region of the G
gene was performed using primer pairs as previously
described [12]. Resulting sequences were assembled and
edited using the SEQMAN II software of the Lasergene
package (DNAstar, Madison, WI) and allocated to sub-
type RSV A or RSV B using the Basic Local Alignment
Search Tool (BLAST; http://blast.ncbi.nlm.nih.gov).
Statistical analysis and data reporting
Statistical analyses were conducted using Stata/IC13.0
(StataCorp. LP, College Station, TX, USA). Mann-
Whitney-U-test was applied to compare CT values in
samples with true positive versus false negative Alere i
RSV result. The Alere i RSV sensitivity in RSV A versus
RSV B positive samples was compared using the χ2-Test.
P values <0.05 were considered statistically significant.
Data reporting was done according to STARD 2015
recommendations [13].
Results
From November 2016 to March 2017, 533 NPS were
collected from 499 children presenting with symptoms
of acute respiratory tract infection. Fifteen samples were
excluded from the final analysis due to unavailability of
sample aliquots for RT-PCR testing (n = 7), duplicate
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sampling of patients during one hospital stay (n = 7), or
missed re-testing of an initially invalid Alere i RSV test
result (n = 1).
Five hundred eighteen samples (97% of 533 collected
NPS) from 492 children were included in the final
analysis (Fig. 1). Demographic and clinical characteristics
of the study participants are summarized in Table 1.
Alere i RSV was positive in 43% (224/518) and
negative in 57% (294/518). In comparison to the RT-
PCR reference standard, the Alere i RSV test result was
true positive in 213 and true negative in 278 samples,
respectively. False positive test results were reported in
11 patients, and 16 patients were identified with false
negative Alere i RSV test outcome (Table 2). The overall
Alere i RSV test sensitivity and specificity was 93% (CI95
89% – 96%) and 96% (CI95 93% – 98%), respectively.
The mean FTD 21 CT value of true positive samples
was 17.7 (CI95 17.1–18.3; range 11.7–34.6). NPS with
false negative Alere i RSV result had a significantly
higher mean CT value of 31.1 (CI95 29.6–32.6; range
25.4–34.5, P < 0.001; Mann-Whitney-U-test).
Fig. 1 Study Flow Chart
Table 1 Baseline demographic and clinical characteristics of 518
study participants
N = 518 n % of total
gender
male 292 57%
female 226 43%
age
0–5 months 212 41%
6–11 months 76 15%
12–23 months 107 21%
≥ 2 years 123 24%
duration of clinical symptoms on admission
≤ 3 days 276 53%
> 3 days 218 42%
unknown 24 5%
admission diagnosis
URTI 81 16%
LRTI 257 49%
non-respiratory 180 35%
We grouped the admission diagnoses in cases of URTI (n = 81, including URTI,
otitis media and croup), LRTI (n = 257, including bronchiolitis, bronchitis and
pneumonia) and non-respiratory admission diagnoses (n = 180). The latter
includes children admitted for non-respiratory reasons (e.g. febrile convulsion,
diarrhea) with concomitant acute RTI
Table 2 Cross tabulation of Alere i RSV test results by the
RT-PCR result
Alere i RSV positive Alere i RSV negative total
RT-PCR positive 213 16 229
RT-PCR negative 11 278 289
total 224 294 518
Schnee et al. BMC Infectious Diseases  (2017) 17:767 Page 3 of 6
RSV A infection was detected in 65% (149 / 229) and
RSV B in 32% (74 / 229) of RSV positive NPS. In two
samples, both RSV A and B were identified. In 4 cases,
no subtype could be determined. The sensitivity of the
Alere i RSV assay was 93% (CI95 87% – 96%) in RSV A
and 96% (CI95 89% – 99%) in RSV B positive samples.
This difference was not statistically significant (P = 0.3,
χ2-Test).
From the clinical perspective, CT values were higher
(and hence viral load lower) in respiratory specimens of
older children and children admitted for non-respiratory
reasons with concomitant respiratory tract infection
(Additional file 1: Table S1). In consequence, the Alere i
RSV sensitivity was 98% (CI95 94% - 100%) in children
<6 months, 94% (CI95 81% - 99%) in children 6–
11 months, 83% (CI95 68% - 93%) in children 12–
23 months and 87% (CI95 73% - 96%) in children above
2 years of age (Table 3). In children hospitalized for
URTI or LRTI, the Alere i RSV test sensitivity was 100%
(CI95 84–100%) and 96% (CI95 92–99%), respectively. In
children who were admitted for non-respiratory reasons,
we found a sensitivity of 77% (CI95 61% – 88%) (Table 3).
As illustrated in Additional file 1: Figure S2, the relatively
poor sensitivity in this group resulted from a high propor-
tion of samples with low viral load (CT value >30), and co-
infection with Influenza A, Parainfluenza, Rhinovirus or
Coronavirus was detected in 5 / 10 cases.
We did not undertake comprehensive analytical speci-
ficity testing but note that the 289 NPS with negative
RT-PCR result included samples tested positive for Influ-
enza A, H1N1 or B (n = 42), Rhinovirus (n = 99),
Bocavirus (n = 23), Adenovirus (n = 18), Parainfluenza 1,
2, 3 or 4 (n = 36), Coronavirus NL63, 229E, OC43 or
HKU1 (n = 41), Parechovirus (n = 3), Enterovirus (n = 3),
Human metapneumovirus A/B (n = 12) and Mycoplasma
pneumoniae (n = 3). In RSV positive specimens, ob-
served coinfections included Rhinovirus (n = 38), Cor-
onavirus (n = 25), Parainfluenza (n = 12), Bocavirus (n =
9) and Influenza (n = 8). In 65 cases, neither RSV nor
any of the above-mentioned pathogens were detected.
In our point-of-care setting, positive test results were
identified after a mean duration of 5.1 min (CI95 4.9–
5.2 min; range 4.7–10.0 min). This included both sample
pre-heating (3 min) and the amplification reaction. After
the first testing, invalid results were reported in 6% (29/
518). These NPS were directly retested, and valid (posi-
tive or negative) results were obtained in all cases.
Discussion
We found that the novel Alere i RSV assay has a sensi-
tivity of 93% (CI95 89% – 96%) and a specificity of 96%
(CI95 93% – 98%) in a pediatric point-of-care setting.
The test is user-friendly and test results are obtained in
less than 13 min, with most positive test results being
identified after approximately 5 min.
No direct comparison of Alere i RSV versus RADT
was done in our study. Based on published data, the
expected RADT sensitivity in young children is approxi-
mately 80% [9]. In our study setting, we previously found
a RADT sensitivity of 63% (CI95 55–72%) [14] and 55%
(CI95 45% – 64%) [15] over two different winter seasons.
The Alere i RSV sensitivity is clearly superior to the
expected RADT performance.
In children aged 24–35 months with lower viral load,
the use of RADT is particularly limited with reported
sensitivity of approximately 60% [16]. In patients ≥2 years
of age, we found an Alere i sensitivity and specificity of
87% and 98% in comparison to our RT-PCR reference
standard, respectively. The Alere i assay is suitable for
point-of-care detection of RSV in children across all age
groups.
Other sensitive rapid nucleic acid amplification assays
are available for early detection of RSV infection. These
assays require a testing time of at least 30 min to more
than 1 h [17, 18]. Alere i RSV test results are available
Table 3 Alere i RSV test sensitivity and specificity by admission diagnosis and age group
Alere i RSV test result total sensitivity in
% (CI95)
Alere i RSV test result total specificity
in % (CI95)true positive false negative true negative false positive
213 16 229 93 (89–96) 278 11 289 96 (93–98)
admission diagnosis
URTI 21 0 21 100 (84–100) 57 3 60 95 (86–99)
LRTI 159 6 165 96 (92–99) 89 3 92 97 (91–99)
non-respiratory 33 10 43 77 (61–88) 133 5 138 96 (92–99)
age group
0–5 months 112 2 114 98 (94–100) 94 4 98 96 (90–99)
6–11 months 33 2 35 94 (81–99) 40 1 41 98 (87–100)
12–23 months 34 7 41 83 (68–93) 62 4 66 94 (85–98)
≥ 2 years 34 5 39 87 (73–96) 83 2 85 98 (92–100)
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within 13 min, and positive test results are called out
after a mean duration of approximately 5 min.
A limitation of our study is the use of VTM for Alere i
RSV testing instead of directly inserting the swab to the
Alere test base. Using VTM was required to establish
the RT-PCR reference standard. This procedure is in
accordance with the Alere i RSV package insert, but im-
plies that samples are 1:5 diluted in comparison to dir-
ectly inserting the swab. In our analysis, this could have
provoked false negative results in samples with low viral
load, and regular point-of-care users might prefer direct,
non-diluted testing of swab specimens. Second, we com-
pared Alere i RSV test results against a multiplex RT-
PCR reference standard. Only divergent results were fur-
ther evaluated by monoplex RT-PCR. Multiplex RT-PCR
is usually slightly less sensitive than monoplex RT-PCR
in samples with low viral load. [19] In pediatric patients,
viral loads are usually high and in fact, 95% of our RSV
positive samples had a CT value <30. We therefore be-
lieve that multiplex RT-PCR is a rigorous reference
standard in our study cohort, but acknowledge that ap-
plying a monoplex RT-PCR reference standard might
have resulted in a slightly lower sensitivity of the Alere i
RSV assay.
In summary, we evaluated the novel Alere i RSV assay
in a pediatric emergency setting against a RT-PCR refer-
ence standard. The Alere i RSV performed well in the
point-of-care setting, and sensitive test results were
obtained across all pediatric age groups within 13 min.
The assay requires a shorter test time than other
currently available molecular test assays, and provides a
significantly higher sensitivity than RADT assays.
Conclusions
The Alere i RSV assay performs well in the pediatric
point-of-care setting. The assay is easy to use, and the
high sensitivity and specificity of test results help pedia-
tricians to act appropriately both in patients with and
without RSV infection.
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